REGENERON PHARMACEUTICALS, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $1.17B, a 10.16% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $794.30M, a 23.73% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $671.70M, a 30.97% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $664.00M, a 9.67% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of common stock for fiscal 2025 was $3.44B, a 32.09% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of common stock for fiscal 2024 was $2.60B, a 16.48% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of common stock for fiscal 2023 was $2.23B, a 7.31% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. payments for repurchase of common stock for fiscal 2022 was $2.08B, a 26.58% increase from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $1.17B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.30B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $794.30M 10-Q · filed 2026-04-29 | $3.19B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $671.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $3.44B 10-K · filed 2026-02-04 |
| 2025-09-30 | $664.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $3.74B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.06B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.81B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.04B 10-Q · filed 2026-04-29 | $3.35B derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $973.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $2.60B 10-K · filed 2026-02-04 |
| 2024-09-30 | $735.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.92B derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-06-30 | $603.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $1.73B derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-03-31 | $291.30M 10-Q · filed 2025-04-29 | $1.82B derived: sum of 4 quarters · filed 2026-02-04 |
| 2023-12-31 | $289.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $2.23B 10-K · filed 2026-02-04 |
| 2023-09-30 | $546.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.38B derived: sum of 4 quarters · filed 2025-02-05 |
| 2023-06-30 | $688.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.77B derived: sum of 4 quarters · filed 2025-02-05 |
| 2023-03-31 | $710.70M 10-Q · filed 2024-05-02 | $2.44B derived: sum of 4 quarters · filed 2025-02-05 |
| 2022-12-31 | $431.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $2.08B 10-K · filed 2025-02-05 |
| 2022-09-30 | $934.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.52B derived: sum of 4 quarters · filed 2024-02-05 |
| 2022-06-30 | $359.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.75B derived: sum of 4 quarters · filed 2024-02-05 |
| 2022-03-31 | $358.10M 10-Q · filed 2023-05-04 | $1.70B derived: sum of 4 quarters · filed 2024-02-05 |
| 2021-12-31 | $866.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $1.65B 10-K · filed 2024-02-05 |
| 2021-09-30 | $166.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.16B derived: sum of 4 quarters · filed 2023-02-06 |
| 2021-06-30 | $305.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.09B derived: sum of 4 quarters · filed 2023-02-06 |
| 2021-03-31 | $306.90M 10-Q · filed 2022-05-04 | $5.83B derived: sum of 4 quarters · filed 2023-02-06 |
| 2020-12-31 | $381.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $5.85B 10-K · filed 2023-02-06 |
| 2020-09-30 | $92.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $5.71B derived: sum of 4 quarters · filed 2022-02-07 |
| 2020-06-30 | $5.05B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $5.64B derived: sum of 4 quarters · filed 2022-02-07 |
| 2020-03-31 | $320.70M 10-Q · filed 2021-05-06 | $586.60M derived: sum of 4 quarters · filed 2022-02-07 |
| 2019-12-31 | $246.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $275.90M 10-K · filed 2022-02-07 |
| 2019-09-30 | $19.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $29.40M derived: sum of 4 quarters · filed 2021-02-08 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $14.40M derived: sum of 4 quarters · filed 2021-02-08 |
| 2019-03-31 | $10.00M 10-Q · filed 2020-05-05 | $14.40M derived: sum of 4 quarters · filed 2021-02-08 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $4.40M 10-K · filed 2021-02-08 |
| 2018-09-30 | $4.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $4.40M derived: sum of 4 quarters · filed 2020-02-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $0.00 10-K · filed 2020-02-07 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |